Recently, some encouraging results have been reported from the critical phase III trial DESTINY-Breast 04, which showed that regardless of HR status PFS and OS were both improved in HER2-low breast cancer patients treated with T-Dxd (29). Here, ERBB2 is linked to breast carcinoma.